Clinical and economic review of erlotinib in non-small-cell lung cancer

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 12, Issue 4, 2012, Pages 411-423

  Yeung, Kai ^a   Carlson, Josh J ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

cost; cost effectiveness; cost utility; erlotinib; lung cancer

Indexed keywords

ANTIBIOTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GEMCITABINE; LOPERAMIDE; PACLITAXEL; PEMETREXED; PLACEBO; STEROID;

CANCER CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; ECONOMIC EVALUATION; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH INSURANCE; HUMAN; LUNG NON SMALL CELL CANCER; MEDICAID; MEDICARE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; REVIEW;

CARCINOMA, NON-SMALL-CELL LUNG; COST-BENEFIT ANALYSIS; DRUG COSTS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MUTATION; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84866664163     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/erp.12.42     Document Type: Review

References (94)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J. Clin. 61(4), 212-236 (2011
2. Center M, Siegel R, Jemal A. American Cancer Society: Global Cancer Facts & Figures (2nd Edition). American Cancer Society Inc., GA, USA (2011
3. Midthun D. Overview of the initial evaluation, treatment and prognosis of lung cancer. In: UpToDate. Basow D (Ed.). UpToDate, MA, USA (2012
4. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Non-Small-Cell Lung Cancer. National Comprehensive Cancer Network, USA (2012
5. Robinson LA, Ruckdeschel JC, Wagner H Jr, Stevens CW; American College of Chest Physicians. Treatment of non-small-cell lung cancer-stage IIIA: ACCP evidencebased clinical practice guidelines (2nd edition). Chest 132(Suppl. 3), S243-S265 (2007
6. Nadler E, Yu E, Ravelo A, Sing A, Forsyth M, Gruschkus S. Bevacizumab treatment to progression after chemotherapy: Outcomes from a U.S. community practice network. Oncologist 16(4), 486-496 (2011
7. Patel JD, Hensing TA, Rademaker A et al. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J. Clin. Oncol. 27(20), 3284-3289 (2009
8. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 355(24), 2542-2550 (2006
9. Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361(10), 947-957 (2009
10. Ramsey SD, Howlader N, Etzioni RD, Donato B. Chemotherapy use, outcomes, and costs for older persons with advanced non-small-cell lung cancer: Evidence from Surveillance, Epidemiology and End Results - Medicare. J. Clin. Oncol. 22(24), 4971-4978 (2004
11. Gervais R, Rosell R, Vergnenegre A. The EURTAC (European Tarceva® vs Chemotherapy) study: Interim results of a Phase III randomized trial of erlotinib vs chemotherapy (CT) in advanced nonsmall- cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) activating mutations. J. Thorac. Oncol. 6(6 Suppl. 2), S314-S315 (2011
12. Zhou C, Wu Y, Chen G. Efficacy results from the randomised Phase III OPTIMAL (CTONG 0802) study comparing first-line erlotinib versus carboplatin (CBDC A) plus gemcitabine (GEM), in Chinese advanced non-small-cell lung cancer (NSCLC patients (pts) with EGFR activating mutations. Ann. Oncol. 21(Suppl. 8), viii6 (2010
13. Zhou C, Wu YL, Chen G et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutationpositive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, Phase 3 study. Lancet Oncol. 12(8), 735-742 (2011
14. Cataldo VD, Gibbons DL, Pérez-Soler R, Quintás-Cardama A. Treatment of non-small-cell lung cancer with erlotinib or gefitinib. N. Engl. J. Med. 364(10), 947-955 (2011
15. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al.; National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-smallcell lung cancer. N. Engl. J. Med. 353(2), 123-132 (2005
16. Gatzemeier U, Pluzanska A, Szczesna A et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: The Tarceva Lung Cancer Investigation Trial. J. Clin. Oncol. 25(12), 1545-1552 (2007
17. Herbst RS, Prager D, Hermann R et al.; TRIBUTE Investigator Group. TRIBUTE: A Phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J. Clin. Oncol. 23(25), 5892-5899 (2005
18. Jänne PA, Rochelle JM, Martin-DeLeon PA, Stambolian D, Seldin MF, Nussbaum RL. Mapping of the 75-kDa inositol polyphosphate-5-phosphatase (Inpp5b to distal mouse chromosome 4 and its exclusion as a candidate gene for dysgenetic lens. Genomics 28(2), 280-285 (1995
19. Rosell R, Carcereny E, Gervais R et al.; Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised Phase 3 trial. Lancet Oncol. 13(3), 239-246 (2012
20. Midthun D. Initial systemic therapy for advanced non-small cell lung cancer with a mutation in the epidermal growth factor receptor. In: UptoDate. Basow D (Ed. UpToDate, MA, USA (2012
21. EMA. Erlotinib (Tarceva) summary of opinion (post authorisation).EMA, London, UK (2011
22. Gridelli C, Maione P, Rossi A et al. Potential treatment options after first-line chemotherapy for advanced NSCLC: Maintenance treatment or early secondline? Oncologist 14(2), 137-147 (2009
23. Neal JW. The SATURN trial: The value of maintenance erlotinib in patients with nonsmall- cell lung cancer. Future Oncol. 6(12), 1827-1832 (2010
24. Miller VA, O'Connor P, Soh C, Kabbinavar F. A randomized, double-blind, placebo-controlled, Phase IIIb trial (ATLAS) comparing bevacizumab (B therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small-cell lung cancer (NSCLC). J. Clin. Oncol. 27(Suppl. 18) (2009) (Abstract LBA8002
25. Belani P, Brodowicz T, Ciuleanu T et al. Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac plus BSC: A randomized Phase III study in advanced non-small-cell lung cancer (NSCLC). J. Clin. Oncol. 27 (2009
26. Permetrexed. Prescribing information. Eli Lilly and Company, IN, USA (2011
27. Tarceva®. Prescribing information. Genentech, CA, USA (2010
28. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 353(2), 123-132 (2005
29. Tsao MS, Sakurada A, Cutz JC et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N. Engl. J. Med. 353(2), 133-144 (2005
30. Chouaid C, Le Caer H, Crequit J et al. Cost-effectiveness of erlotinib in first-line treatment of advanced non-small-cell lung cancer (NSCLC) in fit elderly patients: An economical analysis of a prospective Phase 2 study (GFPC 0504). Value Health 13(7), A267 (2010
31. Krawczyk K et al. The qualification of docetaxel or erlotinib for second-line therapy should be based on clinical and molecular predictive factors. Chemotherapy 58(1), 60-69 (2012
32. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Non-Small-Cell Lung Cancer V.1.2009. National Comprehensive Cancer Network, USA (2009
33. Kim ES, Hirsh V, Mok T et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): A randomised Phase III trial. Lancet 372(9652), 1809-1818 (2008
34. Jones D. Avastin-Tarceva combination fails in lung cancer. Nat. Biotechnol. 27(2), 108-109 (2009
35. Silvestri G, Pritchard R, Welch HG. Preferences for chemotherapy in patients with advanced non-small-cell lung cancer: Descriptive study based on scripted interviews. BMJ 317(7161), 771-775 (1998
36. Juhasz E, Kim JH, Stelmakh L, Cicenas S, Klingelschmitt G. Erlotinib maintenance therapy for non-small-cell lung cancer preserves quality of life. Value Health 13(7), A276-A277 (2010
37. Jatoi A, Nguyen PL. Do patients die from rashes from epidermal growth factor receptor inhibitors? A systematic review to help counsel patients about holding therapy. Oncologist 13(11), 1201-1204 (2008
38. Eaby B, Culkin A, Lacouture ME. An interdisciplinary consensus on managing skin reactions associated with human epidermal growth factor receptor inhibitors. Clin. J. Oncol. Nurs. 12(2), 283-290 (2008
39. Pérez-Soler R, Delord JP, Halpern A et al. HER1/EGFR inhibitor-associated rash: Future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist 10(5), 345-356 (2005
40. Tsuboi M, Le Chevalier T. Interstitial lung disease in patients with non-small-cell lung cancer treated with epidermal growth factor receptor inhibitors. Med. Oncol. 23(2), 161-170 (2006
41. Ohe Y, Fakuoka M, Kudoh S et al. Post-marketing surveillance of erlotinib for NSCLC in Japan: Interim analyses of 3,488 patients. J. Clin. Oncol. 29 (2011
42. Leighl NB, Tsao WS, Zawisza DL, Nematollahi M, Shepherd FA. A willingnessto- pay study of oral epidermal growth factor tyrosine kinase inhibitors in advanced non-small-cell lung cancer. Lung Cancer 51(1), 115-121 (2006
43. van Zandwijk N. Epidermal growth factor tyrosine kinase inhibitors (EGFR TKIs and economics. Lung Cancer 51(1), 137-138 (2006
44. Ramsey SD, Martins RG, Blough DK, Tock LS, Lubeck D, Reyes CM. Secondline and third-line chemotherapy for lung cancer: use and cost. Am. J. Manag. Care 14(5), 297-306 (2008
45. Nuijten MJ, de Castro Carpeño J, Chouaid C et al. A cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non-smallcell lung cancer. Lung Cancer 76(3), 465-471 (2012
46. Lash S, Teitelbaum A, Henk HJ, Reyes CM, Benn L. Costs associated with second-line therapies for lung cancer. Am. J. Pharm. Benefit 3(1), 21-33 (2011
47. Castro De Carpeno J, Castro-Gomez AJ, Walzer S, Ray J. Cost comparison of erlotinib versus pemetrexed for the first-line maintenance treatment of patients with locally advanced or metastatic non-smallcell lung cancer in Spain. Value Health 13(7), A259 (2010
48. Ravera S, Walzer S, Ray J. Cost comparison of erlotinib versus pemetrexed for the first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancer in Italy. Value Health 13(7), A259 (2010
49. Ramsey SD, Clarke L, Kamath TV, Lubeck D. Evaluation of erlotinib in advanced non-small-cell lung cancer: Impact on the budget of a U.S. health insurance plan. J. Manag. Care Pharm. 12(6), 472-478 (2006
50. Carlson JJ, Wong WB, Veenstra DL, Reyes C. Budget impact of erlotinib for maintenance therapy in advanced non-small-cell lung cancer. J. Med. Econ. 14(2), 159-166 (2011
51. Surveillance, Epidemiology and End Results. Surveillance, Epidemiology, and End Results (SEER) program, SEER-17 registry, public use dataset 2004-2007.
52. Surveillance, Epidemiology and End Results, MD, USA (2010
53. Docetaxel. Prescribing information. Hospira, IL, USA (2011
54. Clark O, Clark LG, Botrel TE et al. Budgetary impact of adoption of erlotinib for lung cancer in the private health insurance market in Brazil: A real world data analysis. Value Health 14(7), A438-A439 (2011
55. Carlson JJ, Garrison LP, Ramsey SD, Veenstra DL. The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer. Value Health 12(1), 20-27 (2009
56. Carlson JJ, Reyes C, Oestreicher N, Lubeck D, Ramsey SD, Veenstra DL. Comparative clinical and economic outcomes of treatments for refractory non-small-cell lung cancer (NSCLC). Lung Cancer 61(3), 405-415 (2008
57. Bradbury PA, Tu D, Seymour L et al.; NCIC Clinical Trials Group Working Group on Economic Analysis. Economic analysis: Randomized placebo-controlled clinical trial of erlotinib in advanced non-small-cell lung cancer. J. Natl Cancer Inst. 102(5), 298-306 (2010
58. Dickson R, Bagust A, Boland A et al. Erlotinib monotherapy for the maintenance treatment of non-small-cell lung cancer after previous platinum-containing chemotherapy: A NICE single technology appraisal. Pharmacoeconomics 29(12), 1051-1062 (2011
59. Lewis G, Peake M, Aultman R et al. Cost-effectiveness of erlotinib versus docetaxel for second-line treatment of advanced non-small-cell lung cancer in the United Kingdom. J. Int. Med. Res. 38(1), 9-21 (2010
60. McLeod C, Bagust A, Boland A et al. Erlotinib for the treatment of relapsed non-small-cell lung cancer. Health Technol. Assess. 13(Suppl. 1), 41-47 (2009
61. Hanna N, Shepherd FA, Fossella FV et al. Randomized Phase III trial of pemetrexed versus docetaxel in patients with nonsmall- cell lung cancer previously treated with chemotherapy. J. Clin. Oncol. 22(9), 1589-1597 (2004
62. Shepherd FA, Dancey J, Ramlau R et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J. Clin. Oncol. 18(10), 2095-2103 (2000
63. Cromwell I, van der Hoek K, Melosky B, Peacock S. Erlotinib or docetaxel for second-line treatment of non-small-cell lung cancer: A real-world cost-effectiveness analysis. J. Thorac. Oncol. 6(12), 2097-2103 (2011
64. Vergnenègre A, Ray JA, Chouaid C et al. Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small-cell lung cancer. Clinicoecon. Outcomes Res. 4, 31-37 (2012
65. Nadler E, Forsyth M, Satram-Hoang S, Reyes C. Costs and clinical outcomes among patients with second-line nonsmall- cell lung cancer in the outpatient community setting. J. Thorac. Oncol. 7(1), 212-218 (2012
66. Laurendeau C, Chouaid C, Florentin V, Duchon D'Engenières V, Detournay B. Cost-minimization analysis of second-line chemotherapy for non-small-cell lung cancer (NSCLC). Value Health 14(7), A440 (2011
67. Chouaid C, Le Caer H, Corre R et al. Cost-effectiveness of erlotinib in first line treatment of advanced non-small-cell lung cancer (NSCLC) in vulnerable elderly patients: An economical analysis of a prospective Phase 2 study (GFPC 0505 Value Health 14(7), A448 (2011
68. Pompen M, Novak A, Postmus P. Cost-effectiveness analysis of erlotinib in The Netherlands. Value Health 9(6), A203 (2006
69. Terres R, Sanz A, Gylmark M. Pharmacoeconomic analysis in Spain of therapy with erlotinib, docetaxel, pemetrexed or best supportive care in patients with advanced non-small-cell lung cancer who have failed previous chemotherapy regimens. Value Health 9(6), A283 (2006
70. Lewis G, Morlotti L, Creeden J. Cost-effectiveness of erlotinib compared with docetaxel for the treatment of relapsed non-small-cell lung cancer (NSCLC) in the UK. Value Health 9(6), A203 (2006
71. NICE. ERG report: Erlotinib for the treatment of relapsed non-small-cell lung cancer. NICE, UK (2006
72. Ciuleanu TE, Dediu M, Minea LN, Baculea S, Szkultecka-Debek M. Cost- effectiveness analysis of erlotinib in the treatment of advanced non-small-cell lung cancer (NSCLC) in Romania. Value Health 13(3), A38 (2010
73. Nguyen TT, Yagudina R, Kulikov A. Cost-effectiveness analysis of erlotinib versus docetaxel, pemetrexed for secondline treatment of advanced non-smallcell lung cancer in Russia. Value Health 14(7), A450 (2011
74. Orlewska E, Szczesna A, Gyldmark M. Cost-effectiveness of erlotinib in the treatment of advanced non-small-cell lung cancer (NSCLC) in Poland. Value Health 9(6), A279 (2006
75. Santos EA, Buschinelli CT, Ferracini M, Pepe C, Estanislao M. Erlotinib as second line treatment for advanced non-small-cell lung cancer (NSCLC): Economic modeling (EM) results. Value Health 14(7), A446 (2011
76. Terres R, Sanz A, Gylmark M. Pharmacoeconomic analysis in Spain of therapy with erlotinib, docetaxel, pemetrexed or best supportive care in patients with advanced non-small-cell lung cancer who have failed previous chemotherapy regimens. Value Health 9(6), A283-A284 (2006
77. Borget I, Cadranel J, Mauguen A et al. Cost-effectiveness analysis of three strategies of erlotinib treatment in non-small-cell lung cancer: A prospective multicentric French study (ERMETIC Value Health 13(7), A266 (2010
78. Borget I, Cadranel J, Pignon JP et al.; ERMETIC Collaborative Group. Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmallcell lung cancer: The ERMETIC study part 3. Eur. Respir. J. 39(1), 172-179 (2012
79. Keedy VL, Temin S, Somerfield MR et al. American Society of Clinical Oncology provisional clinical opinion: Epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J. Clin. Oncol. 29(15), 2121-2127 (2011
80. Côté I, Leighl N, Gyldmark M, Maturi B. Pharmacoeconomic analyses of erlotinib compared with best supportive care (BSC for the treatment of relapsed non-small-cell lung cancer (NSCLC) from the Canadian public health care perspective. Value Health 9(6), A279 (2006
81. Keedy VL, Temin S, Somerfield MR et al. American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J. Clin. Oncol. 29(15), 2121-2127 (2011
82. de Lima Lopes G Jr, Segel JE, Tan DS, Do YK, Mok T, Finkelstein EA. Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung. Cancer 118(4), 1032-1039 (2012
83. Brown T, Boland A, Bagust A et al. Gefitinib for the first-line treatment of locally advanced or metastatic non-smallcell lung cancer. Health Technol. Assess. 14(Suppl. 2), 71-79 (2010
84. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350(21), 2129-2139 (2004
85. Paez JG, Jänne PA, Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304(5676), 1497-1500 (2004
86. EMA. Evaluation of Medicines for Human Use. Assessment Report for Iressa®. EMA, London, UK (2012
87. Maemondo M, Inoue A, Kobayashi K et al.; North-East Japan Study Group. Gefitinib or chemotherapy for non-smallcell lung cancer with mutated EGFR. N. Engl. J. Med. 362(25), 2380-2388 (2010
88. Mitsudomi T, Morita S, Yatabe Y et al.; West Japan Oncology Group. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised Phase 3 trial. Lancet Oncol. 11(2), 121-128 (2010
89. Shaw AT, Yeap BY, Solomon BJ et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: A retrospective analysis. Lancet Oncol. 12(11), 1004-1012 (2011
90. Peruzzi B, Bottaro DP. Targeting the c-Met signaling pathway in cancer. Clin. Cancer Res. 12(12), 3657-3660 (2006
91. Ciuleanu T, Stelmakh L, Cicenas S et al. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): A randomised multicentre, open-label, Phase 3 study. Lancet Oncol. 13(3), 300-308 (2012
92. Gridelli C, Ciardiello F, Feld R et al. International multicenter randomized Phase III study of first-line erlotinib (E followed by second-line cisplatin plus gemcitabine (CG) versus first-line CG followed by second-line E in advanced non-small-cell lung cancer (aNSCLC): The TORCH trial. J. Clin. Oncol. 28(15), A7508 (2010
93. Carlson JJ. Erlotinib in non-small-cell lung cancer: A review of the clinical and economic evidence. Expert Rev. Pharmacoecon. Outcomes Res. 9(5), 409-416 (2009
94. Orlewska E, Szczesna A, Gyldmark M. Cost-effectiveness of erlotinib in the treatment of advanced non-small-cell lung cancer (NSCLC) in poland. Value Health 9(6), A280 (2006